| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 2 |
Gupta S, Tao L, Murphy JD, et al. Race/Ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer [J]. Gastroenterology, 2019, 156(1): 59-62.
|
| 3 |
Correa P. Gastric cancer: overview [J]. Gastroenterol Clin North Am, 2013, 42(2): 211-217.
|
| 4 |
Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening [J]. Jpn J Clin Oncol, 2008, 38(4): 259-267.
|
| 5 |
Zhang X, Li M, Chen S, et al. Endoscopic screening in asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review [J]. Gastroenterology, 2018, 155(2): 347-354.
|
| 6 |
Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia [J]. Gastroenterology, 2019 Dec 6. pii: S0016-5085(19)41888-X.
|
| 7 |
Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori [J]. Int J Cancer, 2014, 136(2): 487-490.
|
| 8 |
Evans JA, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the anagement of premalignant and malignant conditions of the stomach [J]. Gastrointest Endosc, 2015, 82(1): 1-8.
|
| 9 |
Pimentel-Nunes P, Libanio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019 [J]. Endoscopy, 2019, 51(4): 365-388.
|
| 10 |
Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication [J]. Gut, 2004, 53(9): 1244-1249.
|
| 11 |
Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years [J]. Aliment Pharmacol Ther, 2018, 47(3): 380-390.
|
| 12 |
Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial [J]. JAMA, 2004, 291(2): 187-194.
|
| 13 |
Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection [J]. Aliment Pharmacol Ther, 2005, 22(5): 471-481.
|
| 14 |
Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system [J]. Gut, 2007, 56(5): 631-636.
|
| 15 |
Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis [J]. Gastrointest Endosc, 2010, 71(7): 1150-1158.
|
| 16 |
Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB, et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions [J]. Endoscopy, 2012, 44(3): 236-246.
|
| 17 |
Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial [J]. Gastrointest Endosc, 2017, 86(5): 857-865.
|